1449117-74-1 Usage
Chemical structure
A synthetic compound with a pyrrole ring, a urea group, and various alkyl groups attached
Function
Inhibitor of the enzyme fatty acid amide hydrolase (FAAH)
Mechanism of action
By inhibiting FAAH, URB597 increases the levels of the endocannabinoid anandamide in the body
Potential therapeutic effects
Pain reduction, anti-inflammatory properties, and improved mood
Potential treatment for conditions
Anxiety, depression, and chronic pain
Research areas
Pharmacology and neurology
Additional potential treatment
Substance abuse and addiction by modulating the brain's reward system
Preclinical studies
Has shown promise in preclinical studies for its potential as a treatment for substance abuse and addiction
Check Digit Verification of cas no
The CAS Registry Mumber 1449117-74-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,9,1,1 and 7 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1449117-74:
(9*1)+(8*4)+(7*4)+(6*9)+(5*1)+(4*1)+(3*7)+(2*7)+(1*4)=171
171 % 10 = 1
So 1449117-74-1 is a valid CAS Registry Number.
1449117-74-1Relevant articles and documents
(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation
Brogi, Simone,Brindisi, Margherita,Butini, Stefania,Kshirsagar, Giridhar U.,Maramai, Samuele,Chemi, Giulia,Gemma, Sandra,Campiani, Giuseppe,Novellino, Ettore,Fiorenzani, Paolo,Pinassi, Jessica,Aloisi, Anna Maria,Gynther, Mikko,Venskutonyte, Raminta,Han, Liwei,Frydenvang, Karla,Kastrup, Jette Sandholm,Pickering, Darryl S.
, p. 2124 - 2130 (2018/03/21)
Starting from 1-4 and 7 structural templates, analogues based on bioisosteric replacements (5a-c vs 1, 2 and 6 vs 7) were synthesized for completing the SAR analysis. Interesting binding properties at GluA2, GluK1, and GluK3 receptors were discovered. The requirements for GluK3 interaction were elucidated by determining the X-ray structures of the GluK3-LBD with 2 and 5c and by computational studies. Antinociceptive potential was demonstrated for GluK1 partial agonist 3 and antagonist 7 (2 mg/kg ip).
